Moms with placenta accreta who undergo insertion of prophylactic arterial balloons reduce risk of complications with delivery and future fertility.
Prophylactic placement of arterial balloons prior to performing a Caesarean section in patients with placenta accreta preserves the uterus, according to new study presented this week at the annual meeting of the Radiological Society of North America (RSNA).
Researchers from Ireland performed a retrospective chart review in order to assess maternal and fetal outcomes from the placement of a prophylactic internal iliac balloon under fluoroscopic guidance among patients with placenta accreta, immediately prior to undergoing elective Caesarean sections.
"Massive obstetric hemorrhage is the number one cause of maternal mortality worldwide and abnormal placental implantation is a major risk factor for this," Patrick Nicholson, MB, BCh, interventional radiologist trainee, Cork University Hospital, said in a release.
A total of 21 patients with placenta accreta or a variant thereof underwent balloon placement at the researchers’ facility over a 44-month period, starting in 2009. Patient mean age was 35, average gestational age was 37 weeks, mean gravidity was 2.8, and mean number of Caesarian sections was 2.4. Mean intraoperative blood loss was 1.4 liters, and the mean number of blood units transfused was two.
Of the 21 deliveries, arterial balloons were inflated in 13, and were deflated and removed when no longer necessary.
Results showed that 23 live infants were delivered with mean Apgar scores of 8.9 at one minute and 9.6 at 10 minutes. No maternal or fetal complications due to the procedure were noted, although two patients did require a hysterectomy.
"Without the balloons, many more of the patients would likely have required a hysterectomy," Nicholson said in the release.
The researchers concluded that prophylactic placement of an internal iliac balloon is a potentially life-saving, fertility preserving procedure that is safe for both mother and infant.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.